[1] LIN S S，WANG Y L. Progress in research of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes [J]. Pharm Clin Res (药学与临床研究)，2009，17（6）：480-485.

 [2] SALVATORE T，C ARBONARA O，COZZOLINO D，et al. Progress in the oral treatment of type 2 diabetes： update on DPP-IV inhibitors[J]. Curr Diabetes Rev，2009，5（2） ： 92-101. 

[3] HEISE T，GRAEFE-MODY E U，HTTNER S，et al. Pharmacokinetics，pharmacodynamics and tolerability of multiple oral doses of linagliptin，a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients[J]. Diabetes Obes Metab，2009，11（8）：786-794. 

[4] BLECH S，LUDWIG-SCHWELLINGER E，GRFE-MODY E U，et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor，linagliptin，in humans[J]. Drug Metab Dispos， 2010，38（4）：667-678.

 [5] SCHEEN A J. Dipeptidylpeptitase-4 inhibitors (gliptins)： focus on drug-drug interactions[J]. Clin Pharmacokinet，2010， 49（9）：573-588. 

[6] DEL PRATO S，BARNETT A H，HUISMANN H，et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes[J]. Diabetes Obes Metab，2011，13（3）：258-267. 

[7] FDA. Label approved on 2/5/2011 for LINAGLIPTIN，NDA no. 201280[EB/OL]. http：//www. accessdata. fda. gov/drugsatfda_docs/label/2011/201280lbl. pdf